Cancel
Click Therapeutics
See Linkedin
Click Therapeutics Employees
12 people indexed:
-
08408g@d8zf04z768ydb1ddq.df3 Sign up to see email
-
j4b31q@d7483d02y68b3jj6v.2y9 Sign up to see email
-
5yw45@zgw9f13q058v80q6g.z6g Sign up to see email
-
b52f4@bngy6z37fb57gb3gg.q7j Sign up to see email
-
d4j@w6z6g407bv0ddqgff.zx9 Sign up to see email
-
111xbw5@gvbgbn0qb4778060w.466 Sign up to see email
-
03nxj268@gnq9b32446nwx76fj.jgy Sign up to see email
-
wv99b59@g91y3jg0xxx58f91x.21b Sign up to see email
-
9w8w22w@qjxwy125bv1875xw5.f8y Sign up to see email
-
7ffz@q6dx0d160nj0ff6yv.bgz Sign up to see email
-
jbz0147@fxf69w69qj1797yyq.wqz Sign up to see email
-
Ted Silver
0b3@ny07jy7524152v4q3.6q1 Sign up to see emailf0g@84w301f2ffzybx9v9.9y4 Sign up to see email
Click Therapeutics Company Information
Click Therapeutics is a biotechnology company that develops and commercializes software as prescription medical treatments for patients with unmet medical needs. The company leverages cognitive and neurobehavioral mechanisms to enable change within individuals, with products designed to be used independently or alongside biomedical treatments. As a regulated Software as a Medical Device (SaMD)-focused company, Click Therapeutics adheres to FDA, ISO, and IEC standards, ensuring that their applications are clinically validated through rigorous randomized, controlled trials to demonstrate safety and efficacy. The company seeks FDA clearance for its apps as class II medical devices, either with independent therapeutic treatment claims or as adjuncts to existing therapy. Click Therapeutics continuously personalizes and improves its applications by generating and applying real-world evidence. Headquartered in New York, NY, with additional offices in Boston, MA, Miami, FL, and Raleigh, NC, the company offers products such as Clickotine® for smoking cessation and Rejoyn™ for Major Depressive Disorder (MDD), along with digital therapeutics for conditions like schizophrenia, migraine, insomnia, and acute coronary syndrome. Click Therapeutics collaborates with companies like Otsuka, Boehringer Ingelheim, Indivior, and Magellan Health to develop and commercialize its digital therapeutics. The company has received FDA Breakthrough Device Designation for prescription digital therapeutics to treat negative symptoms of schizophrenia and episodic migraine. It has secured $30 million in growth capital from K2 HealthVentures and $20 million in debt financing from HSBC. Click Therapeutics conducts fully remote and decentralized clinical trials to evaluate the efficacy and safety of its digital therapeutics and has been awarded a National Institutes of Health (NIH) grant for a digital therapeutic study on smoking cessation. The company recently launched a new brand identity and redesigned its website to reflect its evolution and mission. Named a 2022 Best Place to Work in NYC by BuiltIn, Click Therapeutics develops products on the Click Neurobehavioral Intervention (CNI) platform, powered by Clickometrics®, a machine learning and data science engine. The company engages in value-based, pay-for-performance agreements to improve care while lowering costs and participates in various investor conferences and events to present and discuss its advancements in digital therapeutics.
Report inaccurate information
Report inaccurate information
